Compare EBS & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBS | NAN |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.4M | 356.7M |
| IPO Year | 2006 | N/A |
| Metric | EBS | NAN |
|---|---|---|
| Price | $8.08 | $11.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 79.7K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.37% |
| EPS Growth | ★ 125.83 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $742,900,000.00 | N/A |
| Revenue This Year | $29.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.02 | $10.69 |
| 52 Week High | $14.06 | $11.67 |
| Indicator | EBS | NAN |
|---|---|---|
| Relative Strength Index (RSI) | 28.20 | 40.45 |
| Support Level | $7.66 | $11.37 |
| Resistance Level | $9.68 | $11.50 |
| Average True Range (ATR) | 0.54 | 0.08 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 7.26 | 17.19 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.